

MedCap Q4 2024 - A tale of euphoria and despair

Redeye updates its estimates and valuation following MedCap releasing its Q4 2024 report. After the share's nosedive, we believe it has returned to interesting territory. We judge the share's recent crash also illustrated how high expectations leave little margin for error. While multiples might not recover quickly, we believe there are reasons to be optimistic.

[Read more and download the Research Update.](#)

Follow companies at Redeye to receive the latest equity research within Life Science and Technology.

This is a press release from Redeye - Research Powered Investment Banking. www.redeye.se/

Attachments

[MedCap Q4 2024 - A tale of euphoria and despair](#)